US5104875A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Combination preparations containing rifampicin and thioacetazon
Assignee: FATOL ARZNEIMITTEL ROBERT-KOCH-STRASSE D-6658 SCHIFFWEILER GmbH
•
Filing: 1990-05-15
•
Granted: 1992-04-14
•
Expires: 2010-05-15
Abstract
Abstract Pharmaceutical combination preparations containing rifampicin and thioacetazon and optionally isonicotinic acid hydrazide or ethambutol and the use of same for the treatment of mycobacterial infections.
Inventors
- 👤 Klaus Jurgen
- 👤 Joachim Seydel
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-26 19:16
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/33; A61K31/395; A61K31/495
Claims Analysis
Total Claims: 10
Claim 1
Independent Claim
41 words
A pharmaceutical combination in orally administrable form for the treatment of mycobacterial infections consisting essentially of effective amounts of rifampicin and thioacetazon as the active ingredients in a synergistic weight ratio of rifampicin to thioacetazon of 2 to 6:0.5 to 2.
Claim 2
Dependent Claim
41 words
A pharmaceutical combination in orally administrable form for the treatment of mycobacterial infections consisting essentially of effective amounts of rifampicin and thioacetazon as the active ingredients in a synergistic weight ratio of rifampicin to thioacetazon of 2 to 6:0.5 to 2.
Claim 3
Dependent Claim
23 words
The pharmaceutical combination of claim 1, containing from about 300 to about 700 mg rifampicin and from about 50 to about 100 thioacetazon.
Claim 4
Dependent Claim
16 words
The pharmaceutical combination of claim 2, containing about 400 mg rifampicin and about 75 mg thioacetazon.
Claim 5
Dependent Claim
47 words
A pharmaceutical composition in orally administrable form for the treatment of mycobacterial infections consisting essentially of effective amounts of rifampicin and thioacetazon as the active ingredients in a synergistic weight ratio of rifampicin to thioacetazon of 2 to 6:0.5 to 2; together with a pharmaceutically acceptable carrier.
Claim 6
Dependent Claim
47 words
A pharmaceutical composition in orally administrable form for the treatment of mycobacterial infections consisting essentially of effective amounts of rifampicin and thioacetazon as the active ingredients in a synergistic weight ratio of rifampicin to thioacetazon of 2 to 6:0.5 to 2; together with a pharmaceutically acceptable carrier.
Claim 7
Independent Claim
42 words
A method treating a mycobacterial infection comprising orally administering to a patient having same, an effective amount, in combination, of rifampicin and thioacetazon as the active ingredients in a synergistic weight ratio of rifampicin to thioacetazon of 2 to 6:0.5 to 2.
Claim 8
Independent Claim
42 words
A method treating a mycobacterial infection comprising orally administering to a patient having same, an effective amount, in combination, of rifampicin and thioacetazon as the active ingredients in a synergistic weight ratio of rifampicin to thioacetazon of 2 to 6:0.5 to 2.
Claim 9
Dependent Claim
18 words
The method of claim 5, in which the infection is caused by a mycobacteria of the MOTT complex.
Claim 10
Dependent Claim
18 words
The method of claim 5, in which the infection is caused by a mycobacteria of the avium species.
References Cited (Backward Citations)
US3751567A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1995-04-14 | 1995-10-14 | 1996-04-14 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1999-04-14 | 1999-10-14 | 2000-04-14 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2003-04-14 | 2003-10-14 | 2004-04-14 | $7700.00 | Window Closed / Lapsed |